Senseonics and Sequel Med Tech Partner to Advance Automated Insulin Delivery Systems

In a significant development for diabetes management, Senseonics and Sequel Med Tech have announced a partnership to integrate Senseonics' long-term continuous glucose monitoring (CGM) technology with Sequel's automated insulin delivery (AID) system. This collaboration aims to provide people with Type 1 diabetes a more convenient and effective solution for managing their condition.

Eversense 365 CGM Joins Forces with Twiist Insulin Pump

Senseonics' Eversense 365, a one-year implantable CGM sensor, will now be compatible with Sequel's Twiist automated insulin delivery system. This integration extends the capabilities of the Twiist system, allowing users to benefit from Senseonics' long-term glucose monitoring technology while automating their insulin dosing.

The combined system is scheduled for launch in the third quarter of 2025, marking a significant milestone in diabetes care technology. Tim Goodnow, President and CEO of Senseonics, emphasized the importance of this development, stating, "People with diabetes who choose the convenience and ease of our one-year CGM sensor have been waiting for a compatible AID system to enhance their diabetes management."

Expanding Interoperability in Diabetes Tech

This partnership represents a growing trend towards interoperability in diabetes management devices. Sequel Med Tech has been actively pursuing collaborations to enhance the versatility of its Twiist system. In March 2025, the company announced a partnership with Abbott to integrate the Twiist pump with Abbott's Freestyle Libre 3 Plus Sensor.

The Twiist system, developed in collaboration with Deka Research & Development, received FDA 510(k) clearance in March 2024 for use in people with Type 1 diabetes aged six and up. It incorporates an AID app developed by the nonprofit organization Tidepool and is set for commercial launch in the U.S. in the second quarter of 2025.

Market Impact and Future Prospects

While analysts from BTIG expect limited commercial impact for Senseonics in the initial quarters following the launch, they view this partnership as "the first step in enhancing the interoperability of Eversense beyond a standalone CGM." The collaboration validates Senseonics' product and may pave the way for future integrations with other insulin pump manufacturers.

Mukul Jain, Chief Operating Officer at Senseonics, has indicated that the company is working on multiple fronts to enhance Eversense 365's compatibility with various pump systems. This strategy aligns with the growing demand for flexible and interoperable diabetes management solutions, catering to patients who may switch between different CGMs or pumps over time.

As the diabetes technology landscape continues to evolve, partnerships like this between Senseonics and Sequel Med Tech are likely to play a crucial role in advancing patient care and simplifying diabetes management for millions of people worldwide.